Vancouver, British Columbia (Newsfile Corp. - May 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative
All resolutions submitted for approval were passed by shareholdersVancouver, British Columbia (Newsfile Corp. - May 18, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech
Phase 1b/2a trial expected to commence in Q3 2023First readout anticipated in 2024Vancouver, British Columbia (Newsfile Corp. - April 13, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen"
Vancouver, Canada (Newsfile Corp. - February 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative
Completed NVG-291 dosing of subjects in Phase 1 clinical trialPhase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023NVG-291 has been demonstrated in preclinical